This article has Open Peer Review reports available.
Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)
- Florian Huemer1, 2, 3,
- Josef Thaler4,
- Gudrun Piringer4,
- Hubert Hackl5,
- Lisa Pleyer1, 2, 3,
- Clemens Hufnagl1, 2, 3,
- Lukas Weiss†1, 2, 3 and
- Richard Greil†1, 2, 3Email author
© The Author(s). 2018
Received: 15 April 2017
Accepted: 21 December 2017
Published: 3 January 2018
Open Peer Review reports
Pre-publication versions of this article are available by contacting email@example.com.
|15 Apr 2017||Submitted||Original manuscript|
|18 Jun 2017||Reviewed||Reviewer Report - david tougeron|
|21 Aug 2017||Reviewed||Reviewer Report - Hans Prenen|
|29 Aug 2017||Reviewed||Reviewer Report - Luciano Cascione|
|29 Sep 2017||Author responded||Author comments - Florian Huemer|
|Resubmission - Version 2|
|29 Sep 2017||Submitted||Manuscript version 2|
|2 Oct 2017||Reviewed||Reviewer Report - Hans Prenen|
|1 Dec 2017||Author responded||Author comments - Florian Huemer|
|Resubmission - Version 3|
|1 Dec 2017||Submitted||Manuscript version 3|
|15 Dec 2017||Reviewed||Reviewer Report - Hans Prenen|
|Resubmission - Version 4|
|Submitted||Manuscript version 4|
|21 Dec 2017||Editorially accepted|
|3 Jan 2018||Article published||10.1186/s12885-017-3955-4|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting firstname.lastname@example.org.
You can find further information about the peer review system here.